Rhumbline Advisers grew its position in shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) by 16.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,278 shares of the biotechnology company’s stock after buying an additional 3,626 shares during the quarter. Rhumbline Advisers owned 0.08% of Spark Therapeutics worth $1,570,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Highbridge Capital Management LLC bought a new position in shares of Spark Therapeutics during the 1st quarter valued at $227,000. KCG Holdings Inc. lifted its holdings in shares of Spark Therapeutics by 9.4% during the 1st quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 538 shares during the period. Cornerstone Capital Management Holdings LLC. bought a new position in shares of Spark Therapeutics during the 1st quarter valued at $572,000. American International Group Inc. lifted its holdings in shares of Spark Therapeutics by 17.4% during the 1st quarter. American International Group Inc. now owns 11,582 shares of the biotechnology company’s stock valued at $618,000 after buying an additional 1,714 shares during the period. Finally, Essex Investment Management Co. LLC bought a new position in shares of Spark Therapeutics during the 2nd quarter valued at $647,000. 91.01% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have recently weighed in on ONCE. Jefferies Group LLC reissued a “buy” rating and set a $95.00 price target (up from $85.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Evercore ISI began coverage on Spark Therapeutics in a report on Wednesday, August 16th. They set an “in-line” rating and a $83.00 price target on the stock. Zacks Investment Research raised Spark Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 19th. BidaskClub raised Spark Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, Chardan Capital reissued a “neutral” rating on shares of Spark Therapeutics in a report on Monday, July 24th. Two analysts have rated the stock with a sell rating, two have given a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $84.78.
In related news, insider Daniel Faga sold 3,000 shares of the business’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $85.02, for a total transaction of $255,060.00. Following the completion of the transaction, the insider now directly owns 3,000 shares in the company, valued at $255,060. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barge Joseph La sold 5,500 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $81.00, for a total transaction of $445,500.00. Following the transaction, the insider now owns 10,825 shares of the company’s stock, valued at $876,825. The disclosure for this sale can be found here. Insiders have sold 346,864 shares of company stock valued at $25,142,486 over the last 90 days. 7.30% of the stock is currently owned by insiders.
Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) opened at 85.82 on Wednesday. The stock has a 50 day moving average price of $82.71 and a 200 day moving average price of $82.71. Spark Therapeutics, Inc. has a 1-year low of $35.07 and a 1-year high of $86.20. The stock’s market capitalization is $2.68 billion.
Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). The business had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.04) earnings per share. Equities research analysts anticipate that Spark Therapeutics, Inc. will post ($7.69) EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/09/20/spark-therapeutics-inc-once-shares-bought-by-rhumbline-advisers.html.
Spark Therapeutics Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.